吉利德科学公司(GILD)周二公布的2024年第四季度财报数据表现优异,引发了市场热议。
报告显示,公司第四季度营收同比增长6%至75.69亿美元,高于分析师预期的71.4亿美元。其核心产品艾滋病治疗药物销售额同比大增16%,达到55亿美元,成为推动营收增长的主要动力。
此外,该公司第四季度纯利润同比增长25%至17.83亿美元,每股收益1.9美元也高于分析师平均预期水平。公司对2025年表现持乐观态度,全年销售额和调整后每股收益指引均略高于分析师预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.